IC
GCTK icon

Ikarian Capital’s GlucoTrack GCTK Stock Holding History

Ikarian Capital’s Portfolio GCTK Stock Details GCTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.8K Hold
45,830
– – ﹤0.01% 158
2025
Q4 		$177K Buy
+45,830
New +$272K 0.01% 156

Other funds holding GCTK

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ikarian Capital's GCTK Position: Q1 2026 in Review

Ikarian Capital held its GlucoTrack (GCTK) position steady in Q1 2026 at 45,830 shares worth $29.8K. The position accounts for ﹤0.01% of the portfolio, ranked #158.

Ikarian Capital first reported a position in GCTK in Q4 2025 and has held it in 2 quarters since. The position peaked at $177K in Q4 2025. 13 funds tracked by Wall St. Rank hold GCTK as of Q1 2026.

  • Ikarian Capital held 45,830 shares of GlucoTrack worth $29.8K as of Q1 2026.
  • Ikarian Capital left its GlucoTrack share count unchanged in Q1 2026.
  • GlucoTrack made up ﹤0.01% of Ikarian Capital's portfolio in Q1 2026, its #158 holding.
  • Ikarian Capital first reported a position in GlucoTrack in Q4 2025 and has held it in 2 quarters since.
  • Ikarian Capital's GlucoTrack position peaked at $177K in Q4 2025.
  • 13 funds tracked by Wall St. Rank held GlucoTrack as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.